Illumina to buy rival Pacific Biosciences
Gene sequencing company Illumina Inc. plans to buy Pacific Biosciences of California Inc. in an all-cash deal valued at $1.2 billion.
Featured Posts
Mobile Marketing Special Feature: Growing voice for mobile
Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.
Mobile Marketing Special Feature: Getting pharma into new mobile tech
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
Mobile Marketing Special Feature: Still a case for apps
In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.
Pharma Innovators Special Feature 2018: Focus on innovation
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
AR/VR Special Feature 2018: The new (augmented) reality in life sciences
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
AR/VR Special Feature 2018: Beyond the hype – AR and VR in healthcare
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Payer Access Special Feature: Straining the system
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
Annual Report 2018: State of the Bio Industry
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Consumer/Patient Experience Special Feature: Saving lives isn’t enough anymore
Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.
Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale
It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
Agenda 2018 Special Feature: The song remains the same
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Top 10 Pipelines 2018 Annual Report
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
Special Feature – Value of Medicines: The value equation
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
Sanofi and Denali Reach Potential $1+ Billion Deal
Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.
Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer
Akoya Biosciences Inc., a Telegraph Hill Partners company, acquired PerkinElmer Inc.’s Phenoptics portfolio.
Novartis Cuts 20 Percent of Research Programs
Novartis is abandoning approximately 20 percent of the company’s research projects after a strategic review.
AstraZeneca Divests Two Drugs to Grünenthal
Grünenthal will pay AstraZeneca $700 million up-front for the prescription drug rights to the acid-reflux medicine Nexium. AstraZeneca may also receive future milestones and sales-related payments of up to $90 million.
Eli Lilly, Dicerna Reach RNAi Therapies Deal
Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
Novartis, Pfizer join forces on potentially lucrative fatty liver disease
Novartis AG and Pfizer Inc. are teaming up to develop treatments for a liver disease tied to obesity and diabetes epidemics that many drug companies believe will become a hugely lucrative market.
Abbott, AbbVie settle TriCor marketing case for $25 million
Abbott and AbbVie will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Lundbeck Schizophrenia Drug Fails Phase III Study
Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.
India’s Dr. Reddy’s Q2 profit surges nearly 70 percent
Indian drugmaker Dr. Reddy’s Laboratories posted a 69.7 percent jump in fiscal second-quarter 2018 profit, helped by new product launches.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
October 2018 Focus: Top 50 Pharma, Company of the Year and more!